Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CABA |
---|---|---|
09:32 ET | 11654 | 10.215 |
09:34 ET | 6210 | 10.02 |
09:36 ET | 2720 | 10.02 |
09:38 ET | 1779 | 10.1173 |
09:39 ET | 2090 | 10.09 |
09:41 ET | 1815 | 10.185 |
09:43 ET | 3300 | 10.25 |
09:45 ET | 1400 | 10.27 |
09:48 ET | 1387 | 10.26 |
09:50 ET | 2299 | 10.35 |
09:52 ET | 485 | 10.43 |
09:54 ET | 2507 | 10.49 |
09:56 ET | 1764 | 10.52 |
09:57 ET | 795 | 10.58 |
09:59 ET | 4174 | 10.72 |
10:01 ET | 1599 | 10.71 |
10:03 ET | 989 | 10.68 |
10:06 ET | 5324 | 10.585 |
10:08 ET | 1918 | 10.6535 |
10:10 ET | 1071 | 10.66 |
10:12 ET | 2507 | 10.66 |
10:14 ET | 1345 | 10.71 |
10:15 ET | 893 | 10.76 |
10:17 ET | 2448 | 10.725 |
10:19 ET | 955 | 10.73 |
10:21 ET | 3545 | 10.735 |
10:24 ET | 1556 | 10.68 |
10:26 ET | 1154 | 10.675 |
10:28 ET | 1623 | 10.69 |
10:30 ET | 1690 | 10.77 |
10:32 ET | 1612 | 10.75 |
10:33 ET | 2049 | 10.775 |
10:35 ET | 445 | 10.77 |
10:37 ET | 1277 | 10.87 |
10:39 ET | 1104 | 10.8 |
10:42 ET | 300 | 10.78 |
10:44 ET | 1862 | 10.8 |
10:46 ET | 1637 | 10.845 |
10:48 ET | 800 | 10.845 |
10:50 ET | 2166 | 10.86 |
10:51 ET | 508 | 10.875 |
10:53 ET | 1232 | 10.8601 |
10:55 ET | 845 | 10.9 |
10:57 ET | 936 | 10.87 |
11:00 ET | 2925 | 10.89 |
11:02 ET | 156 | 10.86 |
11:04 ET | 987 | 10.88 |
11:06 ET | 600 | 10.83 |
11:08 ET | 1205 | 10.85 |
11:09 ET | 592 | 10.87 |
11:11 ET | 400 | 10.87 |
11:13 ET | 1861 | 10.82 |
11:15 ET | 1105 | 10.82 |
11:18 ET | 800 | 10.83 |
11:20 ET | 2037 | 10.85 |
11:22 ET | 829 | 10.87 |
11:24 ET | 400 | 10.91 |
11:26 ET | 821 | 10.92 |
11:27 ET | 3062 | 10.87 |
11:29 ET | 100 | 10.9 |
11:33 ET | 1291 | 10.94 |
11:36 ET | 4097 | 10.97 |
11:38 ET | 1965 | 10.975 |
11:40 ET | 1800 | 11.005 |
11:42 ET | 900 | 11.005 |
11:44 ET | 1782 | 10.96 |
11:45 ET | 4586 | 11 |
11:47 ET | 7579 | 11.07 |
11:49 ET | 11465 | 11.1 |
11:51 ET | 2129 | 11.16 |
11:54 ET | 17216 | 11.23 |
11:56 ET | 2078 | 11.2 |
11:58 ET | 565 | 11.28 |
12:00 ET | 400 | 11.29 |
12:02 ET | 1361 | 11.23 |
12:03 ET | 1013 | 11.225 |
12:05 ET | 2175 | 11.22 |
12:07 ET | 100 | 11.2 |
12:09 ET | 2000 | 11.175 |
12:12 ET | 1086 | 11.11 |
12:14 ET | 800 | 11.115 |
12:16 ET | 1850 | 11.125 |
12:18 ET | 3997 | 11.075 |
12:20 ET | 100 | 11.075 |
12:21 ET | 2276 | 11.1199 |
12:23 ET | 1200 | 11.135 |
12:25 ET | 500 | 11.145 |
12:27 ET | 911 | 11.09 |
12:30 ET | 637 | 11.11 |
12:32 ET | 414 | 11.12 |
12:34 ET | 3178 | 11.08 |
12:36 ET | 1000 | 11.09 |
12:38 ET | 668 | 11.1 |
12:39 ET | 400 | 11.13 |
12:41 ET | 1309 | 11.12 |
12:43 ET | 500 | 11.11 |
12:45 ET | 100 | 11.14 |
12:48 ET | 1766 | 11.105 |
12:50 ET | 947 | 11.08 |
12:52 ET | 856 | 11.08 |
12:54 ET | 550 | 11.07 |
12:56 ET | 5606 | 11.13 |
12:57 ET | 1171 | 11.11 |
12:59 ET | 1778 | 11.1 |
01:01 ET | 100 | 11.09 |
01:03 ET | 2118 | 11.055 |
01:06 ET | 1250 | 11.045 |
01:08 ET | 775 | 11.07 |
01:10 ET | 768 | 11.03 |
01:12 ET | 2305 | 11.01 |
01:14 ET | 400 | 11 |
01:15 ET | 1523 | 11.02 |
01:17 ET | 1177 | 10.99 |
01:19 ET | 1505 | 11.01 |
01:21 ET | 521 | 11.03 |
01:24 ET | 1113 | 11.02 |
01:26 ET | 100 | 11.04 |
01:28 ET | 506 | 11.03 |
01:30 ET | 679 | 11.01 |
01:32 ET | 931 | 11.02 |
01:33 ET | 500 | 11.0285 |
01:35 ET | 1228 | 11.01 |
01:37 ET | 754 | 11.02 |
01:39 ET | 4647 | 10.945 |
01:42 ET | 300 | 10.975 |
01:44 ET | 2111 | 11.01 |
01:46 ET | 2959 | 11.01 |
01:48 ET | 730 | 10.995 |
01:50 ET | 420 | 10.98 |
01:51 ET | 500 | 10.965 |
01:53 ET | 200 | 10.965 |
01:55 ET | 1339 | 10.9499 |
01:57 ET | 200 | 10.92 |
02:00 ET | 599 | 10.96 |
02:02 ET | 690 | 10.98 |
02:04 ET | 1417 | 10.965 |
02:06 ET | 800 | 10.93 |
02:08 ET | 300 | 10.89 |
02:09 ET | 1500 | 10.87 |
02:11 ET | 1165 | 10.83 |
02:13 ET | 1489 | 10.83 |
02:15 ET | 400 | 10.82 |
02:18 ET | 500 | 10.82 |
02:20 ET | 1000 | 10.81 |
02:22 ET | 2352 | 10.845 |
02:24 ET | 733 | 10.87 |
02:26 ET | 1100 | 10.79 |
02:27 ET | 456 | 10.77 |
02:29 ET | 409 | 10.77 |
02:31 ET | 1450 | 10.85 |
02:33 ET | 300 | 10.86 |
02:36 ET | 493 | 10.88 |
02:38 ET | 900 | 10.9 |
02:40 ET | 1071 | 10.97 |
02:42 ET | 3625 | 11 |
02:44 ET | 1708 | 11 |
02:45 ET | 700 | 10.975 |
02:47 ET | 3335 | 10.965 |
02:49 ET | 7866 | 11.01 |
02:51 ET | 9862 | 10.93 |
02:54 ET | 3918 | 10.91 |
02:56 ET | 5413 | 10.95 |
02:58 ET | 400 | 10.96 |
03:00 ET | 409 | 10.95 |
03:02 ET | 1300 | 10.95 |
03:03 ET | 100 | 10.97 |
03:05 ET | 790 | 11 |
03:07 ET | 1543 | 11.01 |
03:09 ET | 1837 | 10.98 |
03:12 ET | 400 | 10.97 |
03:14 ET | 331 | 10.99 |
03:16 ET | 2886 | 10.975 |
03:18 ET | 1100 | 10.99 |
03:20 ET | 1397 | 11.02 |
03:21 ET | 1318 | 11.02 |
03:23 ET | 100 | 11.019 |
03:25 ET | 449 | 11.06 |
03:27 ET | 4979 | 10.97 |
03:30 ET | 1798 | 11.01 |
03:32 ET | 600 | 11.01 |
03:34 ET | 100 | 11.01 |
03:36 ET | 2157 | 11.01 |
03:38 ET | 600 | 11.02 |
03:41 ET | 800 | 11.03 |
03:43 ET | 3977 | 10.99 |
03:45 ET | 600 | 10.99 |
03:48 ET | 3424 | 11.005 |
03:50 ET | 3769 | 10.97 |
03:52 ET | 5683 | 10.9275 |
03:54 ET | 6662 | 10.92 |
03:56 ET | 17308 | 10.94 |
03:57 ET | 12619 | 10.975 |
03:59 ET | 29045 | 10.99 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Cabaletta Bio Inc | 539.2M | -6.4x | --- |
Aerovate Therapeutics Inc | 544.5M | -7.2x | --- |
Mind Medicine (MindMed) Inc | 533.3M | -2.7x | --- |
Fulcrum Therapeutics Inc | 537.6M | -5.1x | --- |
Third Harmonic Bio Inc | 562.6M | -18.7x | --- |
Altimmune Inc | 517.6M | -3.9x | --- |
Cabaletta Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). CABA-201, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $508.8M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 48.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.47 |
EPS | $-1.73 |
Book Value | $4.94 |
P/E Ratio | -6.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.